APOL1 Risk Variants, Race, and Progression of Cl

New England Journal of Medicine
369, 2183-2196
DOI: 10.1056/nejmoa1310345

Citation Report

#	Article	IF	Citations
1	Health Disparities in Kidney Disease â€" Emerging Data from the Human Genome. New England Journal of Medicine, 2013, 369, 2260-2261.	13.9	16
2	Return of results in the genomic medicine projects of the eMERGE network. Frontiers in Genetics, 2014, 5, 50.	1.1	40
3	Systems Biology and Systems Medicine: The Technological Tools of the System Approaches to Complexity. , 2014, 4, .		0
4	African Americans, hypertension and the renin angiotensin system. World Journal of Cardiology, 2014, 6, 878.	0.5	51
5	Polymorphisms of genes involved in lipid metabolism and risk of chronic kidney disease in Japanese - cross-sectional data from the J-MICC study. Lipids in Health and Disease, 2014, 13, 162.	1.2	7
6	Association between ratio of measured extracellular volume to expected body fluid volume and renal outcomes in patients with chronic kidney disease: a retrospective single-center cohort study. BMC Nephrology, 2014, 15, 189.	0.8	44
7	How can genetics and epigenetics help the nephrologist improve the diagnosis and treatment of chronic kidney disease patients?. Nephrology Dialysis Transplantation, 2014, 29, 972-980.	0.4	13
8	Association of a Polymorphism in a Gene Encoding a Urate Transporter with CKD Progression. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1059-1065.	2.2	51
9	Critical Blood Pressure Threshold Dependence of Hypertensive Injury and Repair in a Malignant Nephrosclerosis Model. Hypertension, 2014, 64, 801-807.	1.3	19
10	Geneâ€"Gene and Geneâ€"Environment Interactions in Apolipoprotein L1 Gene-Associated Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 2006-2013.	2.2	90
11	Developments in renal pharmacogenomics and applications in chronic kidney disease. Pharmacogenomics and Personalized Medicine, 2014, 7, 251.	0.4	7
12	Race, Class, and AKI. Journal of the American Society of Nephrology: JASN, 2014, 25, 1615-1617.	3.0	4
13	Familial Clustering of ESRD in the Norwegian Population. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1692-1700.	2.2	80
14	Association of Sickle Cell Trait With Chronic Kidney Disease and Albuminuria in African Americans. JAMA - Journal of the American Medical Association, 2014, 312, 2115.	3.8	167
15	High-impact session from kidney week. Nature Reviews Nephrology, 2014, 10, 1-1.	4.1	1
16	HIV-Associated Renal and Genitourinary Comorbidities in Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, S68-S78.	0.9	22
17	Disparities in the burden, outcomes, and care of chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2014, 23, 298-305.	1.0	90
18	Focus on Lipids: High-Density Lipoprotein Cholesterol and Its Associated Lipoproteins in Cardiac and Renal Disease. Nephron Clinical Practice, 2014, 127, 158-164.	2.3	6

#	Article	IF	Citations
19	Genetic Variants and Risk of Chronic Kidney Disease. Peritoneal Dialysis International, 2014, 34, 150-150.	1.1	2
20	Coding Variants in Nephrin (NPHS1) and Susceptibility to Nephropathy in African Americans. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1434-1440.	2.2	15
21	Mining for single nucleotide variants (SNVs) at the kallikrein locus with predicted functional consequences. Biological Chemistry, 2014, 395, 1037-1050.	1.2	4
22	Generalizability of Genetic Findings Related to Kidney Function and Albuminuria. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 8-11.	2.2	1
24	Beyond â€œEthnicityâ€•in Dermatology. Dermatologic Clinics, 2014, 32, ix-xii.	1.0	2
25	Lipid biology of the podocyteâ€”new perspectives offer new opportunities. Nature Reviews Nephrology, 2014, 10, 379-388.	4.1	91
26	The Primary Care Physician/Nephrologist Partnership in Treating Chronic Kidney Disease. Primary Care - Clinics in Office Practice, 2014, 41, 837-856.	0.7	5
27	CKD hotspots around the world: where, why and what the lessons are. A CKJ review series. CKJ: Clinical Kidney Journal, 2014, 7, 519-523.	1.4	53
28	Enabling the genomic revolution in Africa. Science, 2014, 344, 1346-1348.	6.0	361
29	APOL1 Kidney Risk Alleles: Population Genetics and Disease Associations. Advances in Chronic Kidney Disease, 2014, 21, 426-433.	0.6	158
30	The Pathogenesis of Focal Segmental Glomerulosclerosis. Advances in Chronic Kidney Disease, 2014, 21, 408-416.	0.6	86
31	FSGS: Forme Pleine or Forme Fruste. Advances in Chronic Kidney Disease, 2014, 21, 395-397.	0.6	2
32	COMT met allele differentially predicts risk versus severity of aberrant eating in a large community sample. Psychiatry Research, 2014, 220, 513-518.	1.7	10
33	Preparation for hypertension specialists:. Journal of the American Society of Hypertension, 2014, 8, 607-611.	2.3	2
35	Clinical Perspectives on Lupus Genetics. Rheumatic Disease Clinics of North America, 2014, 40, 413-432.	0.8	6
37	Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of clinical practice. Clinical Practice (London, England), 2014, 11, 139-143.	0.1	0
38	Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy. Haematologica, 2015, 100, 1275-1284.	1.7	60
39	The associations of malnutrition and aging with fluid volume imbalance between intra- and extracellular water in patients with chronic kidney disease. Journal of Nutrition, Health and Aging, 2015, 19, 986-993.	1.5	28

#	Article	IF	Citations
40	First Report on the OPTN National Variance: Allocation of A2/A2B Deceased Donor Kidneys to Blood Group B Increases Minority Transplantation. American Journal of Transplantation, 2015, 15, 3134-3142.	2.6	32
41	Diagnosing kidney disease in the genetic era. Current Opinion in Nephrology and Hypertension, 2015, 24, 1.	1.0	8
42	Negative health implications of sickle cell trait in high income countries: from the football field to the laboratory. British Journal of Haematology, 2015, 170, 5-14.	1.2	46
43	Recognition and Management of Hypertension in Older Persons: Focus on African Americans. Journal of the American Geriatrics Society, 2015, 63, 2130-2138.	1.3	13
44	Race, Relationship and Renal Diagnoses After Living Kidney Donation. Transplantation, 2015, 99, 1723-1729.	0.5	48
45	In vivo Modeling Implicates APOL1 in Nephropathy: Evidence for Dominant Negative Effects and Epistasis under Anemic Stress. PLoS Genetics, 2015, 11, e1005349.	1.5	45
46	Recent advances in understanding of chronic kidney disease. F1000Research, 2015, 4, 1212.	0.8	27
47	Hypertension in Minority Populations: New Guidelines and Emerging Concepts. Advances in Chronic Kidney Disease, 2015, 22, 145-153.	0.6	26
48	Pro: 'The usefulness of biomarkers in glomerular diseases'. The problem: moving from syndrome to mechanism--individual patient variability in disease presentation, course and response to therapy. Nephrology Dialysis Transplantation, 2015, 30, 892-898.	0.4	15
49	Insuficiencia renal crÃ³nica o enfermedad renal crÃ³nica. EMC - Tratado De Medicina, 2015, 19, 1-8.	0.0	1
50	Comparison of the Rate of Renal Function Decline in NonProteinuric Patients With and Without Diabetes. American Journal of the Medical Sciences, 2015, 350, 447-452.	0.4	23
51	Re-Sequencing of the <i>APOL1</i>-<i>APOL4</i> and <i>MYH9</i> Gene Regions in African Americans Does Not Identify Additional Risks for CKD Progression. American Journal of Nephrology, 2015, 42, 99-106.	1.4	13
52	Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis. American Journal of Nephrology, 2015, 42, 25-34.	1.4	41
53	Epithelial Sodium Transport and Its Control by Aldosterone: The Story of Our Internal Environment Revisited. Physiological Reviews, 2015, 95, 297-340.	13.1	217
54	Socioeconomic Disparities in Chronic Kidney Disease. Advances in Chronic Kidney Disease, 2015, 22, 6-15.	0.6	166
55	Genome-Wide Association Studies in Nephrology: Using Known Associations for Data Checks. American Journal of Kidney Diseases, 2015, 65, 217-222.	2.1	8
57	Effects of Sevelamer Carbonate on Advanced Glycation End Products and Antioxidant/Pro-Oxidant Status in Patients with Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 759-766.	2.2	62
58	Clinical phenotype of APOL1 nephropathy in young relatives of patients with end-stage renal disease. Pediatric Nephrology, 2015, 30, 983-989.	0.9	15

#	Article	IF	Citations
59	Biomarkers for kidney involvement in pediatric lupus. Biomarkers in Medicine, 2015, 9, 529-543.	0.6	20
60	APOL1 Kidney Disease Risk Variants: An Evolving Landscape. Seminars in Nephrology, 2015, 35, 222-236.	0.6	125
61	Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus. American Heart Journal, 2015, 170, 322-329.e4.	1.2	32
62	Opportunities and Challenges of Genotyping Patients With Nephrotic Syndrome in the Genomic Era. Seminars in Nephrology, 2015, 35, 212-221.	0.6	15
63	Genome-wide studies to identify risk factors for kidney disease with a focus on patients with diabetes. Nephrology Dialysis Transplantation, 2015, 30, iv26-iv34.	0.4	41
64	Apolipoprotein L1 Gene Variants in Deceased Organ Donors Are Associated With Renal Allograft Failure. American Journal of Transplantation, 2015, 15, 1615-1622.	2.6	149
65	Racial Differences and Racial Disparities. Circulation, 2015, 131, 848-850.	1.6	14
66	The Influence of HIV and Schistosomiasis on Renal Function: A Cross-sectional Study among Children at a Hospital in Tanzania. PLoS Neglected Tropical Diseases, 2015, 9, e0003472.	1.3	16
67	APOL1 Genotyping of African American Deceased Organ Donors: Not Just Yet. American Journal of Transplantation, 2015, 15, 1457-1458.	2.6	17
68	Risk factors for renal disease in systemic lupus erythematosus and their clinical implications. Expert Review of Clinical Immunology, 2015, 11, 837-848.	1.3	9
69	Human Heredity and Health (H3) in Africa Kidney Disease Research Network. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2279-2287.	2.2	43
70	Testing for High-Risk APOL1 Alleles in Potential Living Kidney Donors. American Journal of Kidney Diseases, 2015, 66, 396-401.	2.1	43
71	Gout after Living Kidney Donation: Correlations with Demographic Traits and Renal Complications. American Journal of Nephrology, 2015, 41, 231-240.	1.4	27
72	APOL1 and Kidney Disease: New Insights Leading to Novel Therapies. American Journal of Kidney Diseases, 2015, 66, 9-11.	2.1	9
73	The role of reninâ€“angiotensinâ€“aldosterone system genes in the progression of chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. Nephrology Dialysis Transplantation, 2015, 30, 1711-1718.	0.4	22
74	New Insights on the Risk for Cardiovascular Disease in African Americans. Journal of the American Society of Nephrology: JASN, 2015, 26, 247-257.	3.0	46
75	Future Translational Applications From the Contemporary Genomics Era. Circulation, 2015, 131, 1715-1736.	1.6	38
76	Apolipoprotein L1, income and early kidney damage. BMC Nephrology, 2015, 16, 14.	0.8	13

#	Article	IF	Citations
77	Nephrosclerosis: A Term in Quest of a Disease. Nephron, 2015, 129, 276-282.	0.9	49
78	Influence of socioeconomic status on allograft and patient survival following kidney transplantation. Nephrology, 2015, 20, 426-433.	0.7	8
79	Arterial stiffness and chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2015, 24, 47-53.	1.0	56
80	The genetics of diabetic complications. Nature Reviews Nephrology, 2015, 11, 277-287.	4.1	124
81	APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans. Journal of the American Society of Nephrology: JASN, 2015, 26, 2882-2890.	3.0	256
82	Renal Autoregulation in Health and Disease. Physiological Reviews, 2015, 95, 405-511.	13.1	348
83	Nephrology researchâ€"the past, present and future. Nature Reviews Nephrology, 2015, 11, 677-687.	4.1	23
84	Focal segmental glomerulosclerosis: molecular genetics and targeted therapies. BMC Nephrology, 2015, 16, 101.	0.8	45
85	Kidney transplant results in children: progress made, but blacks lag behind. Kidney International, 2015, 87, 492-494.	2.6	6
86	Apolipoprotein L1: from obscurity to consistency to controversy. Kidney International, 2015, 87, 14-17.	2.6	10
87	Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2128-2135.	2.2	31
88	APOL1 G1 genotype modifies the association between HDLC and kidney function in African Americans. BMC Genomics, 2015, 16, 421.	1.2	9
89	APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes. Kidney International, 2015, 87, 176-181.	2.6	71
90	Chronic Renal Insufficiency Cohort Study (CRIC). Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2073-2083.	2.2	87
91	Trends in the outcomes of end-stage renal disease secondary to human immunodeficiency virus-associated nephropathy. Nephrology Dialysis Transplantation, 2015, 30, 1734-1740.	0.4	51
92	Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial. Kidney International, 2015, 87, 169-175.	2.6	71
93	Sequencing rare and common APOL1 coding variants to determine kidney disease risk. Kidney International, 2015, 88, 754-763.	2.6	30
94	Hemostatic Factors, APOL1 Risk Variants, and the Risk of ESRD in the Atherosclerosis Risk in Communities Study. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 784-790.	2.2	20

#	Article	IF	Citations
95	Food Access, Chronic Kidney Disease, and Hypertension in the U.S.. American Journal of Preventive Medicine, 2015, 49, 912-920.	1.6	89
96	APOL1 Risk Alleles Are Associated with Exaggerated Age-Related Changes in Glomerular Number and Volume in African-American Adults. Journal of the American Society of Nephrology: JASN, 2015, 26, 3179-3189.	3.0	36
97	APOL1 genetic variants, chronic kidney diseases and hypertension in mixed ancestry South Africans. BMC Genetics, 2015, 16, 69.	2.7	14
98	Novel DNA methylation profiles associated with key gene regulation and transcription pathways in blood and placenta of growth-restricted neonates. Epigenetics, 2015, 10, 50-61.	1.3	57
99	End-Stage Renal Disease Among HIV-Infected Adults in North America. Clinical Infectious Diseases, 2015, 60, 941-949.	2.9	142
100	Causes and pathogenesis of focal segmental glomerulosclerosis. Nature Reviews Nephrology, 2015, 11, 76-87.	4.1	249
101	Histopathologic findings associated with APOL1 risk variants in chronic kidney disease. Modern Pathology, 2015, 28, 95-102.	2.9	49
102	Effect of Genetic African Ancestry on eGFR and Kidney Disease. Journal of the American Society of Nephrology: JASN, 2015, 26, 1682-1692.	3.0	75
103	The Association Between APOL1 Risk Alleles and Longitudinal Kidney Function Differs by HIV Viral Suppression Status. Clinical Infectious Diseases, 2015, 60, 646-652.	2.9	38
104	Estimating Time to ESRD Using Kidney Failure Risk Equations: Results From the African American Study of Kidney Disease and Hypertension (AASK). American Journal of Kidney Diseases, 2015, 65, 394-402.	2.1	45
105	Mechanisms and biological functions of autophagy in diseased and ageing kidneys. Nature Reviews Nephrology, 2015, 11, 34-45.	4.1	81
106	Lack of Association of the APOL1 G3 Haplotype in African Americans with ESRD. Journal of the American Society of Nephrology: JASN, 2015, 26, 1021-1025.	3.0	5
107	Genetics and Chronic Kidney Disease. , 2015, , 213-226.		0
108	Classification of Chronic Kidney Disease â€“ Historic Perspective. , 2015, , 20-30.		0
109	Defining nephrotic syndrome from an integrative genomics perspective. Pediatric Nephrology, 2015, 30, 51-63.	0.9	23
110	Ethnic Differences in Childhood Nephrotic Syndrome. Frontiers in Pediatrics, 2016, 4, 39.	0.9	93
111	Renal and Cardiovascular Morbidities Associated with APOL1 Status among African-American and Non-African-American Children with Focal Segmental Glomerulosclerosis. Frontiers in Pediatrics, 2016, 4, 122.	0.9	29
112	Association between Low Dietary Protein Intake and Geriatric Nutrition Risk Index in Patients with Chronic Kidney Disease: A Retrospective Single-Center Cohort Study. Nutrients, 2016, 8, 662.	1.7	20

#	Article	IF	Citations
113	The evolving science of apolipoprotein-L1 and kidney disease. Current Opinion in Nephrology and Hypertension, 2016, 25, 217-225.	1.0	10
114	APOL1 Polymorphisms in a Deceased Donor and Early Presentation of Collapsing Glomerulopathy and Focal Segmental Glomerulosclerosis in Two Recipients. American Journal of Transplantation, 2016, 16, 1923-1927.	2.6	19
115	Long-term trends in the prevalence of chronicÂkidney disease and the influence ofÂcardiovascularÂrisk factors in Norway. Kidney International, 2016, 90, 665-673.	2.6	40
116	Genomic approaches to the burden of kidney disease in Sub-Saharan Africa: the Human Heredity and Health in Africa (H3Africa) Kidney Disease Research Network. Kidney International, 2016, 90, 2-5.	2.6	25
117	Functional and transport analyses of CLCN5 genetic changes identified in Dent disease patients. Physiological Reports, 2016, 4, e12776.	0.7	13
118	Biomarkers for predicting outcomes in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2016, 25, 480-486.	1.0	26
119	Genetics of Familial FSGS. Seminars in Nephrology, 2016, 36, 467-472.	0.6	8
120	The next generation of therapeutics for chronic kidney disease. Nature Reviews Drug Discovery, 2016, 15, 568-588.	21.5	201
121	Social Determinants of Racial Disparities in CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 2576-2595.	3.0	209
122	Beyond APOL1: Genetic Inroads into Understanding Population Disparities in Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 928-931.	2.2	2
123	Controversies surrounding percutaneous coronary intervention in the diabetic patient. Expert Review of Cardiovascular Therapy, 2016, 14, 633-648.	0.6	3
124	CKD Progression and Mortality among Hispanics and Non-Hispanics. Journal of the American Society of Nephrology: JASN, 2016, 27, 3488-3497.	3.0	40
125	APOL1 renal-risk genotypes associate with longer hemodialysis survival in prevalent nondiabetic African American patients with end-stage renal disease. Kidney International, 2016, 90, 389-395.	2.6	25
126	Apolipoprotein L1 and Kidney Disease in African Americans. Trends in Endocrinology and Metabolism, 2016, 27, 204-215.	3.1	72
127	APOL1-associated glomerular disease among African-American children: a collaboration of the Chronic Kidney Disease in Children (CKiD) and Nephrotic Syndrome Study Network (NEPTUNE) cohorts. Nephrology Dialysis Transplantation, 2017, 32, gfw061.	0.4	60
128	Risk of ESRD in the United States. American Journal of Kidney Diseases, 2016, 68, 862-872.	2.1	59
129	The development of targeted new agents to improve the outcome for children with leukemia. Expert Opinion on Drug Discovery, 2016, 11, 1111-1122.	2.5	7
130	Introducing Genetic Tests With Uncertain Implications in Living Donor Kidney Transplantation. Progress in Transplantation, 2016, 26, 203-206.	0.4	26

#	Article	IF	Citations
131	A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 679-683.	0.7	2
132	Developmental Origins for Kidney Disease Due to Shroom3 Deficiency. Journal of the American Society of Nephrology: JASN, 2016, 27, 2965-2973.	3.0	43
133	Insights into kidney diseases from genome-wide association studies. Nature Reviews Nephrology, 2016, 12, 549-562.	4.1	85
134	Chronic kidney disease in children. CKJ: Clinical Kidney Journal, 2016, 9, 583-591.	1.4	167
135	LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes population. Journal of Diabetes and Its Complications, 2016, 30, 1631-1639.	1.2	5
136	The Patterns, Risk Factors, and Prediction of Progression in Chronic Kidney Disease: A Narrative Review. Seminars in Nephrology, 2016, 36, 273-282.	0.6	38
137	Decreased renal function and associated factors in cities, towns and rural areas of Tanzania: a communityâ€based population survey. Tropical Medicine and International Health, 2016, 21, 393-404.	1.0	14
138	Ethnic Differences in Incidence and Outcomes of Childhood Nephrotic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1760-1768.	2.2	88
139	Trends in Prevalence of Chronic Kidney Disease in the United States. Annals of Internal Medicine, 2016, 165, 473.	2.0	432
140	Research Needs to Improve Hypertension Treatment and Control in African Americans. Hypertension, 2016, 68, 1066-1072.	1.3	78
141	KIDNEY DISEASE GENETICS AND THE IMPORTANCE OF DIVERSITY IN PRECISION MEDICINE. , 2016, , .		2
142	Are There Clinical Implications of Racial Differences in HbA1c? A Difference, to Be a Difference, Must Make a Difference. Diabetes Care, 2016, 39, 1462-1467.	4.3	79
143	APOL1 risk variants and death among African American hemodialysis patients: survival of the fittest?. Kidney International, 2016, 90, 249-252.	2.6	2
144	Combined Effects of GSTM1 Null Allele and APOL1 Renal Risk Alleles in CKD Progression in the African American Study of Kidney Disease and Hypertension Trial. Journal of the American Society of Nephrology: JASN, 2016, 27, 3140-3152.	3.0	38
145	Nivolumab in melanoma. Expert Review of Anticancer Therapy, 2016, 16, 1247-1261.	1.1	20
146	Pharmacogenomics of heart failure: a systematic review. Pharmacogenomics, 2016, 17, 1817-1858.	0.6	10
147	Racial differences in renal replacement therapy initiation among children with a nonglomerular cause of chronic kidney disease. Annals of Epidemiology, 2016, 26, 780-787.e1.	0.9	35
148	Arterial Stiffness and Chronic Kidney Disease. Pulse, 2016, 3, 229-241.	0.9	41

#	Article	IF	Citations
150	Inflammation and Progression of CKD: The CRIC Study. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1546-1556.	2.2	300
151	Patterns of Kidney Function Decline Associated with APOL1 Genotypes: Results from AASK. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1353-1359.	2.2	17
152	Determining the effects and challenges of incorporating genetic testing into primary care management of hypertensive patients with African ancestry. Contemporary Clinical Trials, 2016, 47, 101-108.	0.8	35
153	APOL1nephropathy: from gene to mechanisms of kidney injury. Nephrology Dialysis Transplantation, 2016, 31, 349-358.	0.4	90
154	Analytical Validation of a Personalized Medicine APOL1 Genotyping Assay for Nondiabetic Chronic Kidney Disease Risk Assessment. Journal of Molecular Diagnostics, 2016, 18, 260-266.	1.2	10
155	Hypertension-attributed nephropathy: what's in a name?. Nature Reviews Nephrology, 2016, 12, 27-36.	4.1	69
156	Genome-wide association studies in pediatric chronic kidney disease. Pediatric Nephrology, 2016, 31, 1241-1252.	0.9	9
158	Actualizing the Benefits of Genomic Discovery in Pediatric Nephrology. Journal of Pediatric Genetics, 2016, 05, 069-075.	0.3	1
159	Genetic African Ancestry and Markers of Mineral Metabolism in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 653-662.	2.2	14
160	APOL1 Genotype, Kidney and Cardiovascular Disease, and Death in Older Adults. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 398-403.	1.1	78
161	APOL1 Variants. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 219-220.	1.1	6
162	Primary glomerulonephritides. Lancet, The, 2016, 387, 2036-2048.	6.3	202
163	Ethnic Disparities in CKD in the Netherlands: The Healthy Life in an Urban Setting (HELIUS) Study. American Journal of Kidney Diseases, 2016, 67, 391-399.	2.1	21
164	Lipotoxicity as a trigger factor of renal disease. Journal of Nephrology, 2016, 29, 603-610.	0.9	88
165	Race, APOL1 Risk, and eGFR Decline in the General Population. Journal of the American Society of Nephrology: JASN, 2016, 27, 2842-2850.	3.0	123
166	Association of APOL1 Genotype with Renal Histology among Black HIV-Positive Patients Undergoing Kidney Biopsy. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 262-270.	2.2	27
167	APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 830-837.	3.3	170
168	APOL1nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans. Nephrology Dialysis Transplantation, 2016, 31, 602-608.	0.4	23

#	Article	IF	Citations
169	Predicting Progression in CKD: Perspectives and Precautions. American Journal of Kidney Diseases, 2016, 67, 779-786.	2.1	24
170	APOL1 Genotype and Race Differences in Incident Albuminuria and Renal Function Decline. Journal of the American Society of Nephrology: JASN, 2016, 27, 887-893.	3.0	115
171	Clinical applications of molecular genetic discoveries. Translational Research, 2016, 168, 6-14.	2.2	5
172	How complicated can it be? The link betweenAPOL1risk variants and lipoprotein heterogeneity in kidney and cardiovascular diseases. Nephrology Dialysis Transplantation, 2016, 31, 509-511.	0.4	0
173	Integrative Genomics Identifies Novel Associations with APOL1 Risk Genotypes in Black NEPTUNE Subjects. Journal of the American Society of Nephrology: JASN, 2016, 27, 814-823.	3.0	110
174	Testing the trajectory difference in a semi-parametric longitudinal model. Statistical Methods in Medical Research, 2017, 26, 1519-1531.	0.7	3
175	A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials. Pharmacogenomics Journal, 2017, 17, 192-200.	0.9	11
176	APOL1 genotype, blood pressure, and survival in African Americans with nondiabetic nephropathy. Kidney International, 2017, 91, 276-278.	2.6	3
177	APOL1 Gene Kidney Risk Variants and Cardiovascular Disease: Getting to the Heart of the Matter. American Journal of Kidney Diseases, 2017, 70, 281-289.	2.1	22
178	Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. Nature Medicine, 2017, 23, 429-438.	15.2	282
179	ApoL1 and the Immune Response of Patients with Systemic Lupus Erythematosus. Current Rheumatology Reports, 2017, 19, 13.	2.1	20
180	Sickle Cell Trait and the Risk of ESRD in Blacks. Journal of the American Society of Nephrology: JASN, 2017, 28, 2180-2187.	3.0	79
181	Transplant genetics and genomics. Nature Reviews Genetics, 2017, 18, 309-326.	7.7	60
182	Impact of Autologous Stem Cell Transplantation on Blood Pressure and Renal Function in Multiple Myeloma Patients. Journal of the National Medical Association, 2017, 109, 182-191.	0.6	5
183	Living Organ Donation and Informed Consent in the United States: Strategies to Improve the Process. Journal of Law, Medicine and Ethics, 2017, 45, 66-76.	0.4	12
184	Chronic kidney disease in low-income to middle-income countries: the case for increased screening. BMJ Global Health, 2017, 2, e000256.	2.0	123
185	APOL1 genetic variants are not associated with longitudinal blood pressure in young black adults. Kidney International, 2017, 92, 964-971.	2.6	17
186	Perceived Discrimination and Longitudinal Change in Kidney Function Among Urban Adults. Psychosomatic Medicine, 2017, 79, 824-834.	1.3	42

#	Article	IF	Citations
187	APOL1 Risk Variants and Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1765-1769.	1.1	37
188	Therapeutics for APOL1 nephropathies: putting out the fire in the podocyte. Nephrology Dialysis Transplantation, 2017, 32, i65-i70.	0.4	27
189	<scp>HIV</scp> in the dialysis population: Current issues and future directions. Seminars in Dialysis, 2017, 30, 430-437.	0.7	11
190	Precision Medicine Approaches to Diabetic Kidney Disease: Tissue as an Issue. Current Diabetes Reports, 2017, 17, 30.	1.7	27
191	Hemodialysis Disparities in African Americans: The Deeply Integrated Concept of Race in the Social Fabric of Our Society. Seminars in Dialysis, 2017, 30, 213-223.	0.7	49
192	Apolipoprotein L1 VariantsÂand Blood Pressure Traits inÂAfrican Americans. Journal of the American College of Cardiology, 2017, 69, 1564-1574.	1.2	46
193	The public health dimension of chronic kidney disease: what we have learnt over the past decade. Nephrology Dialysis Transplantation, 2017, 32, ii113-ii120.	0.4	22
194	APOL1 , Î±-thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia. Haematologica, 2017, 102, e1-e6.	1.7	47
195	APOL1: a case in point for replacing race with genetics. Kidney International, 2017, 91, 768-770.	2.6	9
196	Hypertension in Blacks. Hypertension, 2017, 69, 761-769.	1.3	20
197	Strict blood pressure control associates with decreased mortality risk by APOL1 genotype. Kidney International, 2017, 91, 443-450.	2.6	31
198	A perspective on chronic kidney disease progression. American Journal of Physiology - Renal Physiology, 2017, 312, F375-F384.	1.3	98
199	APOL1 Nephropathy: A Population Genetics and Evolutionary Medicine Detective Story. Seminars in Nephrology, 2017, 37, 490-507.	0.6	37
200	Hypertension in African Americans. Current Cardiology Reports, 2017, 19, 129.	1.3	59
201	The spectrum of sickle hemoglobin-related nephropathy: from sickle cell disease to sickle trait. Expert Review of Hematology, 2017, 10, 1087-1094.	1.0	41
202	APOL1 Risk Variants, Incident Proteinuria, and Subsequent eGFR Decline in Blacks with Hypertension-Attributed CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1771-1777.	2.2	30
203	Recurrent glomerular disease after kidney transplantation. Current Opinion in Nephrology and Hypertension, 2017, 26, 501-508.	1.0	12
204	APOL1 and Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1587-1589.	1.1	8

#	Article	IF	Citations
205	Prevalence of Predialysis Kidney Disease in Disadvantaged Populations in Developed Countries: United States. , 2017, , 15-25.		0
206	Racial Differences in Kidney Disease and End-Stage Kidney Disease in the USA. , 2017, , 65-75.		2
207	End Stage Renal Disease in Sub-Saharan Africa. , 2017, , 125-137.		61
208	Apolipoprotein L1 confers pH-switchable ion permeability to phospholipid vesicles. Journal of Biological Chemistry, 2017, 292, 18344-18353.	1.6	39
209	APOL1 and blood pressure changes in young adults. Kidney International, 2017, 92, 793-795.	2.6	11
210	Analytic Considerations for Repeated Measures of eGFR in Cohort Studies of CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1357-1365.	2.2	39
211	Diversity and inclusion in genomic research: why the uneven progress?. Journal of Community Genetics, 2017, 8, 255-266.	0.5	236
212	A New Mouse Model of APOL1 -Associated Kidney Diseases: When Traffic Gets Snarled, the Podocyte Suffers. American Journal of Kidney Diseases, 2017, 70, 460-463.	2.1	2
213	Kidney Disease in HIV: Moving beyond HIV-Associated Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 3142-3154.	3.0	24
215	APOL1 and Proteinuria in the AASK. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1723-1725.	2.2	2
216	The Expanding Role of APOL1 Risk in Chronic Kidney Disease and Cardiovascular Disease. Seminars in Nephrology, 2017, 37, 520-529.	0.6	10
217	A tripartite complex of suPAR, APOL1 risk variants and Î±vÎ²3 integrin on podocytes mediates chronic kidney disease. Nature Medicine, 2017, 23, 945-953.	15.2	176
218	Does copy number variation of APOL1 gene affect the susceptibility to focal segmental glomerulosclerosis?. Renal Failure, 2017, 39, 500-504.	0.8	2
219	Apolipoprotein L1 Genetic Variants Are Associated with Chronic Kidney Disease but Not with Cardiovascular Disease in a Population Referred for Cardiac Catheterization. CardioRenal Medicine, 2017, 7, 96-103.	0.7	8
220	Lack of association between Kidd blood group system and chronic kidney disease. Revista Brasileira De Hematologia E Hemoterapia, 2017, 39, 301-305.	0.7	6
221	The genomic landscape of African populations in health and disease. Human Molecular Genetics, 2017, 26, R225-R236.	1.4	64
222	Family Aggregation and Heritability of ESRD in Taiwan: A Population-Based Study. American Journal of Kidney Diseases, 2017, 70, 619-626.	2.1	31
223	Changes in Urinary Biomarkers Over 10 Years Is Associated With Viral Suppression in a Prospective Cohort of Women Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, e138-e145.	0.9	3

#	Article	IF	Citations
224	Pharmacogenomic implications of the evolutionary history of infectious diseases in Africa. Pharmacogenomics Journal, 2017, 17, 112-120.	0.9	22
225	African Ancestryâ€"Specific Alleles and Kidney Disease Risk in Hispanics/Latinos. Journal of the American Society of Nephrology: JASN, 2017, 28, 915-922.	3.0	57
226	Beginning the trajectory to ESKD in adult life: albuminuria in Australian aboriginal children and adolescents. Pediatric Nephrology, 2017, 32, 119-129.	0.9	12
227	Genome-Wide Association of CKD Progression: The Chronic Renal Insufficiency Cohort Study. Journal of the American Society of Nephrology: JASN, 2017, 28, 923-934.	3.0	55
228	The conundrums of chronic kidney disease and aging. Journal of Nephrology, 2017, 30, 477-483.	0.9	26
229	APOL1â€"Mediated Cell Injury Involves Disruption of Conserved Trafficking Processes. Journal of the American Society of Nephrology: JASN, 2017, 28, 1117-1130.	3.0	88
230	Association Between APOL1 Genotypes and Risk of Cardiovascular Disease in MESA (Multiâ€Ethnic) Tj ETQq0 0 0 rgBT /Overlock	1.6	17
231	Establishing the presence or absence of chronic kidney disease: Uses and limitations of formulas estimating the glomerular filtration rate. World Journal of Methodology, 2017, 7, 73-92.	1.1	26
232	A Culture of Understanding: Reflections and Suggestions from a Genomics Research Community Board. Progress in Community Health Partnerships: Research, Education, and Action, 2017, 11, 161-165.	0.2	25
233	A Classification Model to Predict the Rate of Decline of Kidney Function. Frontiers in Medicine, 2017, 4, 97.	1.2	6
234	Multiple Targets for Novel Therapy of FSGS Associated with Circulating Permeability Factor. BioMed Research International, 2017, 2017, 1-14.	0.9	25
235	How the genomics revolution could finally help Africa. Nature, 2017, 544, 20-22.	13.7	36
236	Race, Genomics and Chronic Disease: What Patients with African Ancestry Have to Say. Journal of Health Care for the Poor and Underserved, 2017, 28, 248-260.	0.4	29
237	Hyperuricemia as a Predictive Marker for Progression of Nephrosclerosis: Clinical Assessment of Prognostic Factors in Biopsy-Proven Arterial/Arteriolar Nephrosclerosis. Journal of Atherosclerosis and Thrombosis, 2017, 24, 630-642.	0.9	26
238	Clustering of chronic kidney disease and cardiovascular risk factors in South-West Nigeria. Journal of Nephropathology, 2017, 6, 196-203.	0.1	10
239	Serious Non-AIDS Conditions in HIV: Benefit of Early ART. Current HIV/AIDS Reports, 2018, 15, 162-171.	1.1	16
240	HDL in CKDâ€"The Devil Is in the Detail. Journal of the American Society of Nephrology: JASN, 2018, 29, 1356-1371.	3.0	65
242	Risk Factors for Prognosis in Patients With Severely Decreased GFR. Kidney International Reports, 2018, 3, 625-637.	0.4	35

#	Article	IF	Citations
243	Update in Pediatric Nephrology. , 2018, , 391-413.		0
244	Addressing Racial Disparity in the Progression of Chronic Kidney Disease: Prescribe More Fruits and Vegetables?. American Journal of Nephrology, 2018, 47, 171-173.	1.4	4
245	Genetic Testing in Clinical Settings. American Journal of Kidney Diseases, 2018, 72, 569-581.	2.1	33
246	Nondepressive Psychosocial Factors and CKD Outcomes in Black Americans. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 213-222.	2.2	16
247	Genetic risk of APOL1 and kidney disease in children and young adults of African ancestry. Current Opinion in Pediatrics, 2018, 30, 252-259.	1.0	30
248	Relationship of Highâ€Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin. Journal of the American Heart Association, 2018, 7, .	1.6	3
249	Global Transcriptome Analysis of RNA Abundance Regulation by ADAR in Lung Adenocarcinoma. EBioMedicine, 2018, 27, 167-175.	2.7	23
250	Precision Medicine for Acute Kidney Injury (AKI): Redefining AKI by Agnostic Kidney Tissue Interrogation and Genetics. Seminars in Nephrology, 2018, 38, 40-51.	0.6	28
251	HLA-DQA1 and APOL1 as Risk Loci for Childhood-Onset Steroid-Sensitive and Steroid-Resistant Nephrotic Syndrome. American Journal of Kidney Diseases, 2018, 71, 399-406.	2.1	41
252	Linking Race, Cancer Outcomes, and Tissue Repair. American Journal of Pathology, 2018, 188, 317-328.	1.9	12
253	Plasma biomarkers are associated with renal outcomes in individuals with APOL1 risk variants. Kidney International, 2018, 93, 1409-1416.	2.6	25
254	Race/Ethnicity, Dietary Acid Load, and Risk of End-Stage Renal Disease among US Adults with Chronic Kidney Disease. American Journal of Nephrology, 2018, 47, 174-181.	1.4	18
255	Familial clustering of hypertensive target organ damage in the community. Journal of Hypertension, 2018, 36, 1086-1093.	0.3	6
257	Apolipoprotein L1 and Chronic Kidney Disease Risk in Young Potential Living Kidney Donors. Annals of Surgery, 2018, 267, 1161-1168.	2.1	44
258	APOL1 Risk Variants Independently Associated With Early Cardiovascular Disease Death. Kidney International Reports, 2018, 3, 89-98.	0.4	14
259	Genome-wide association studies of albuminuria: towards genetic stratification in diabetes?. Journal of Nephrology, 2018, 31, 475-487.	0.9	13
260	APOL1 nephropathy risk variants do not associate with subclinical atherosclerosis or left ventricular mass in middle-aged black adults. Kidney International, 2018, 93, 727-732.	2.6	18
261	Lessons from CKD-Related Genetic Association Studiesâ€"Moving Forward. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 140-152.	2.2	19

#	Article	IF	Citations
262	Simultaneous Pancreas and Kidney Transplantation is Associated With Inferior Long-Term Outcomes in African Americans. Pancreas, 2018, 47, 116-121.	0.5	11
263	Novel avenues for drug discovery in diabetic kidney disease. Expert Opinion on Drug Discovery, 2018, 13, 65-74.	2.5	15
264	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology, 2018, 71, e127-e248.	1.2	4,042
265	Genetic variants and acute kidney injury: A review of the literature. Journal of Critical Care, 2018, 44, 203-211.	1.0	16
266	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension, 2018, 71, e13-e115.	1.3	3,332
267	The role of prognostic assessment with biomarkers in chronic kidney disease: a narrative review. Journal of Laboratory and Precision Medicine, 2018, 3, 12-12.	1.1	1
268	Chronic Kidney Disease and Older African American Adults: How Embodiment Influences Self-Management. Geriatrics (Switzerland), 2018, 3, 52.	0.6	7
269	The ABCs of chronic kidney disease. JAAPA: Official Journal of the American Academy of Physician Assistants, 2018, 31, 17-25.	0.1	4
270	Genetics of Obesity in Diverse Populations. Current Diabetes Reports, 2018, 18, 145.	1.7	27
271	The sickle cell trait and end stage renal disease in Salvador, Brazil. PLoS ONE, 2018, 13, e0209036.	1.1	8
272	Worldwide Frequencies of APOL1 Renal Risk Variants. New England Journal of Medicine, 2018, 379, 2571-2572.	13.9	69
273	The clinical imperative for inclusivity: Race, ethnicity, and ancestry (REA) in genomics. Human Mutation, 2018, 39, 1713-1720.	1.1	102
274	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2018, 138, e484-e594.	1.6	330
275	APOL1-Associated Nephropathy: A Key Contributor to Racial Disparities in CKD. American Journal of Kidney Diseases, 2018, 72, S8-S16.	2.1	113
276	Toxic Metals and Chronic Kidney Disease: a Systematic Review of Recent Literature. Current Environmental Health Reports, 2018, 5, 453-463.	3.2	43
277	ESRD among Immigrants to Ontario, Canada: A Population-Based Study. Journal of the American Society of Nephrology: JASN, 2018, 29, 1948-1959.	3.0	12
278	Incidence and Progression of Chronic Kidney Disease in Black and White Individuals with Type 2 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 884-892.	2.2	23
279	Serum 6-Bromotryptophan Levels Identified as a Risk Factor for CKD Progression. Journal of the American Society of Nephrology: JASN, 2018, 29, 1939-1947.	3.0	13

#	Article	IF	Citations
280	Diabetes and Trajectories of Estimated Glomerular Filtration Rate: A Prospective Cohort Analysis of the Atherosclerosis Risk in Communities Study. Diabetes Care, 2018, 41, 1646-1653.	4.3	43
281	Blocking the 5â€² splice site of exon 4 by a morpholino oligomer triggers APOL1 protein isoform switch. Scientific Reports, 2018, 8, 8739.	1.6	12
282	Anemia (Hemoglobin â‰¤ 13 g/dL) as a Risk Factor for Contrast-Induced Acute Kidney Injury Following Coronary Angiography. American Journal of Cardiology, 2018, 122, 961-965.	0.7	28
283	What is the Role of Soluble Urokinase-Type Plasminogen Activator in Renal Disease?. Nephron, 2018, 139, 334-341.	0.9	20
284	Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1013-1021.	2.2	23
285	APOL1 risk variants and kidney disease: what we know so far. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2018, 40, 388-402.	0.4	18
286	Genetics, Genomics, and Precision Medicine in End-Stage Kidney Disease. Seminars in Nephrology, 2018, 38, 317-324.	0.6	12
287	Epidemiology of End-Stage Renal Disease and Kidney Transplantation. , 2018, , 335-341.		0
288	Views Of Primary Care Providers On Testing Patients For Genetic Risks For Common Chronic Diseases. Health Affairs, 2018, 37, 793-800.	2.5	56
289	Pediatric Nephrologist and the Infant or Child Before Kidney Transplantation. , 2018, , 83-92.		0
290	Ethnicity matching and outcomes after kidney transplantation in the United Kingdom. PLoS ONE, 2018, 13, e0195038.	1.1	16
291	APOL1 risk variants cause podocytes injury through enhancing endoplasmic reticulum stress. Bioscience Reports, 2018, 38, .	1.1	44
292	Racial Disparities in Nephrology Consultation and Disease Progression among Veterans with CKD: An Observational Cohort Study. Journal of the American Society of Nephrology: JASN, 2018, 29, 2563-2573.	3.0	20
293	Hyperfiltration-mediated Injury in the Remaining Kidney of a Transplant Donor. Transplantation, 2018, 102, 1624-1635.	0.5	35
294	Molecular Basis of Kidney Disease. , 2018, , 531-553.		3
295	Greater Burden of ESRD among Immigrants: Kwa nini?. Journal of the American Society of Nephrology: JASN, 2018, 29, 1789-1790.	3.0	0
296	Dose Modification and Dose Titration. , 2018, , 101-151.		1
297	Evidence of chronic kidney disease in veterans with incident diabetes mellitus. PLoS ONE, 2018, 13, e0192712.	1.1	26

#	Article	IF	Citations
298	Ambient air pollution, asthma drug response, and telomere length in African American youth. Journal of Allergy and Clinical Immunology, 2019, 144, 839-845.e10.	1.5	24
299	Apolipoprotein L1, Cardiovascular Disease and Hypertension. Cardiology Clinics, 2019, 37, 327-334.	0.9	4
301	More Evidence to Suggest a Relation of Blood Pressure to Long-term Progression of Kidney Disease: Is It Causal?. American Journal of Kidney Diseases, 2019, 74, 293-296.	2.1	2
302	APOL1 and kidney cell function. American Journal of Physiology - Renal Physiology, 2019, 317, F463-F477.	1.3	19
303	JC Virus and APOL1 Risk Alleles in Black South Africans With Hypertension-Attributed CKD. Kidney International Reports, 2019, 4, 939-945.	0.4	10
304	The Impact of APOL1 on Chronic Kidney Disease and Hypertension. Advances in Chronic Kidney Disease, 2019, 26, 131-136.	0.6	9
305	Urine 5MedC, a Marker of DNA Methylation, in the Progression of Chronic Kidney Disease. Disease Markers, 2019, 2019, 1-10.	0.6	11
306	Chronic Kidney Disease Diagnosis and Management. JAMA - Journal of the American Medical Association, 2019, 322, 1294.	3.8	774
307	Genetics and ESKD Disparities in African Americans. American Journal of Kidney Diseases, 2019, 74, 811-821.	2.1	36
308	Prevalence and predictors of chronic kidney disease among Ghanaian patients with hypertension and diabetes mellitus: A multicenter crossâ€sectional study. Journal of Clinical Hypertension, 2019, 21, 1542-1550.	1.0	45
309	A collaborative, individual-level analysis compared longitudinal outcomes across the International Network of Chronic Kidney Disease (iNETCKD) cohorts. Kidney International, 2019, 96, 1217-1233.	2.6	33
310	APOL1 gene variants and kidney disease in whites: the cardiovascular health study. Nephrology Dialysis Transplantation, 2019, 34, 2155-2156.	0.4	0
311	Burden, access, and disparities in kidney disease. Journal of Nephrology, 2019, 32, 1-8.	0.9	8
312	Association of Fitness With Racial Differences in Chronic Kidney Disease. American Journal of Preventive Medicine, 2019, 57, 68-76.	1.6	3
313	APOL1, Acid Load, and CKD Progression. Kidney International Reports, 2019, 4, 946-954.	0.4	8
314	A Focus on APOL1 and Kidney Disease. Kidney International Reports, 2019, 4, 901-903.	0.4	1
315	Chronic Kidney Disease in Children: Risk-Based Stratification and Treatment. Current Treatment Options in Pediatrics, 2019, 5, 45-60.	0.2	0
317	Association Between Hypertension and Kidney Function Decline: The Atherosclerosis Risk in Communities (ARIC)ÂStudy. American Journal of Kidney Diseases, 2019, 74, 310-319.	2.1	45

#	Article	IF	Citations
318	APOL1 highâ€risk genotypes and renal transplantation. Clinical Transplantation, 2019, 33, e13582.	0.8	9
319	The Genomic Medicine Integrative Research Framework: A Conceptual Framework for Conducting Genomic Medicine Research. American Journal of Human Genetics, 2019, 104, 1088-1096.	2.6	35
320	Dilemmas and challenges in apolipoprotein L1 nephropathy research. Current Opinion in Nephrology and Hypertension, 2019, 28, 77-86.	1.0	7
321	APOL1-Associated Kidney Disease in Brazil. Kidney International Reports, 2019, 4, 923-929.	0.4	24
322	Survival Advantage of African American Dialysis Patients with End-Stage Renal Disease Causes Related to APOL1. CardioRenal Medicine, 2019, 9, 212-221.	0.7	8
323	Burden, Access, and Disparities in Kidney Disease. Blood Purification, 2019, 48, 32-39.	0.9	7
324	Burden, access and disparities in kidney disease. Internal Medicine Journal, 2019, 49, 287-294.	0.5	0
325	Using Human Genetics to Drive Drug Discovery: A Perspective. American Journal of Kidney Diseases, 2019, 74, 111-119.	2.1	7
326	Burden, Access, and Disparities in Kidney Disease. American Journal of Hypertension, 2019, 32, 433-439.	1.0	1
327	Burden, access and disparities in kidney disease. Nephrology Dialysis Transplantation, 2019, 34, 371-376.	0.4	1
328	Poor accordance to a DASH dietary pattern isÂassociated with higher risk of ESRD amongÂadultsÂwith moderate chronic kidneyÂdiseaseÂandÂhypertension. Kidney International, 2019, 95, 1433-1442.	2.6	50
329	Burden, Access, and Disparities in Kidney Disease. American Journal of Nephrology, 2019, 49, 254-262.	1.4	8
330	Reprint of: Burden, access, and disparities in kidney disease. Nephrologie Et Therapeutique, 2019, 15, 3-8.	0.2	0
331	Children with sickle cell anemia and APOL1 genetic variants develop albuminuria early in life. Haematologica, 2019, 104, e385-e387.	1.7	26
332	Burden, access, and disparities in kidney disease. Brazilian Journal of Medical and Biological Research, 2019, 52, e8338.	0.7	21
333	Burden, Access, andÂDisparities in Kidney Disease. Kidney International Reports, 2019, 4, 372-379.	0.4	8
334	Burden, Access, and Disparities in Kidney Disease. Nephron, 2019, 141, 219-226.	0.9	11
335	Burden, Access, and Disparities in Kidney Disease. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811983612.	0.6	2

#	Article	IF	Citations
336	2019 World Kidney Day Editorial - burden, access, and disparities in kidney disease. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2019, 41, 1-9.	0.4	41
337	You Are Just Now Telling Us About This? African American Perspectives of Testing for Genetic Susceptibility to Kidney Disease. Journal of the American Society of Nephrology: JASN, 2019, 30, 526-530.	3.0	31
339	Burden, access and disparities in kidney disease. CKJ: Clinical Kidney Journal, 2019, 12, 160-166.	1.4	12
340	The Future of Genomic Studies Must Be Globally Representative: Perspectives from PAGE. Annual Review of Genomics and Human Genetics, 2019, 20, 181-200.	2.5	33
341	Successful recruitment and retention of diverse participants in a genomics clinical trial: a good invitation to a great party. Genetics in Medicine, 2019, 21, 2364-2370.	1.1	26
342	Burden, Access, and Disparities in Kidney Disease. Kidney Medicine, 2019, 1, 6-12.	1.0	2
343	Association of Adolescent Hypertension With Future End-stage Renal Disease. JAMA Internal Medicine, 2019, 179, 517.	2.6	58
344	Burden, access and disparities in kidney disease. Nephrology, 2019, 24, 373-379.	0.7	1
345	Revisiting racial differences in ESRD due to ADPKD in the United States. BMC Nephrology, 2019, 20, 55.	0.8	10
346	Burden, access, and disparities in kidney disease. Pediatric Nephrology, 2019, 34, 541-548.	0.9	5
347	Hepcidin in chronic kidney disease anemia. Vitamins and Hormones, 2019, 110, 243-264.	0.7	14
348	Burden, Access, and Disparities in Kidney Disease. Kidney Diseases (Basel, Switzerland), 2019, 5, 126-134.	1.2	2
349	Focal Segmental Glomerulosclerosis, Adult. , 2019, , 137-167.		0
350	Cases in Precision Medicine: APOL1 and Genetic Testing in the Evaluation of Chronic Kidney Disease and Potential Transplant. Annals of Internal Medicine, 2019, 171, 659.	2.0	13
351	APOL1 Kidney Risk Variants and Cardiovascular Disease: An Individual Participant Data Meta-Analysis. Journal of the American Society of Nephrology: JASN, 2019, 30, 2027-2036.	3.0	26
352	Nefroangioesclerosis. Medicine, 2019, 12, 4765-4771.	0.0	0
353	Pharmacogenomics and Infectious Diseases in Africa. , 2019, , 95-127.		0
354	One Actor, Many Roles: Histopathologies Associated With APOL1 Genetic Variants. Advances in Anatomic Pathology, 2019, 26, 215-219.	2.4	5

#	Article	IF	Citations
355	Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy. Pharmacogenetics and Genomics, 2019, 29, 18-22.	0.7	10
356	Apolipoprotein L1 Testing in African Americans: Involving the Community in Policy Discussions. American Journal of Nephrology, 2019, 50, 303-311.	1.4	22
358	Uddanam Kidney Nephropathy Under the Light of Metagenomics Perspective. SN Comprehensive Clinical Medicine, 2019, 1, 23-25.	0.3	1
360	Human Population Genetics/Genomics and Society. , 2019, , 437-473.		3
361	Chronic Kidney Disease and Hypertension. , 2019, , 135-143.		1
362	Hypertension Management in African Americans: The AASK and Other Landmark Trial Application. , 2019, , 145-154.		0
364	The Genetics of Diabetic Nephropathy. , 2019, , 89-112.		1
365	Burden, access, and disparities in kidney disease. Kidney International, 2019, 95, 242-248.	2.6	38
366	Non-communicable diseases in migrants: an expert review. Journal of Travel Medicine, 2019, 26, .	1.4	71
367	Statins and Incidence of Contrast-Induced Acute Kidney Injury Following Coronary Angiography - Five Year Experience at a Tertiary Care Center. Cardiovascular Revascularization Medicine, 2019, 20, 654-658.	0.3	3
368	Zebrafish as a model for kidney function and disease. Pediatric Nephrology, 2019, 34, 751-762.	0.9	61
369	Non-immunologic allograft loss in pediatric kidney transplant recipients. Pediatric Nephrology, 2019, 34, 211-222.	0.9	9
370	Examining How Our Shared Evolutionary History Shapes Future Disease Outcomes. Global Heart, 2019, 12, 169.	0.9	2
371	Intakes of long-chain omega-3 polyunsaturated fatty acids and non-fried fish in relation to incidence of chronic kidney disease in young adults: a 25-year follow-up. European Journal of Nutrition, 2020, 59, 399-407.	1.8	14
372	Carga, acceso y disparidades en enfermedad renal. Nefrologia, 2020, 40, 4-11.	0.2	2
373	APOL1 Nephropathy Risk Alleles and Mortality in African American Adults: A Cohort Study. American Journal of Kidney Diseases, 2020, 75, 54-60.	2.1	7
374	Burden, access, and disparities in kidney disease. Nefrologia, 2020, 40, 4-11.	0.2	0
375	Epidemiology of Chronic Kidney Diseaseâ€"Scope of the Problem. , 2020, , 75-89.		3

#	Article	IF	Citations
376	Ethnicity and Chronic Kidney Disease in Africa. , 2020, , 149-166.		2
377	Genetics and Chronic Kidney Disease. , 2020, , 375-396.		0
378	Approach to the Patient with Hypertensive Nephrosclerosis. , 2020, , 737-752.		1
379	APOL1 and Kidney Disease: From Genetics to Biology. Annual Review of Physiology, 2020, 82, 323-342.	5.6	81
380	Classification of Chronic Kidney Diseaseâ€"Historic Perspective: From Insufficiency and Failure to Chronic Kidney Disease. , 2020, , 23-36.		0
381	Myeloperoxidase and the Risk of CKD Progression, Cardiovascular Disease, and Death in the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2020, 76, 32-41.	2.1	17
382	Update on hypertension in African-Americans. Progress in Cardiovascular Diseases, 2020, 63, 33-39.	1.6	42
383	Neural control of cardiovascular function in black adults: implications for racial differences in autonomic regulation. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2020, 318, R234-R244.	0.9	16
385	Race and Mortality in CKD and Dialysis: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2020, 75, 394-403.	2.1	22
386	Slope of Kidney Function and Its Association with Longitudinal Mortality and Cardiovascular Disease among Individuals with CKD. Journal of the American Society of Nephrology: JASN, 2020, 31, 2912-2923.	3.0	16
387	The Relationship Between Immigration Status and Chronic Kidney Disease Risk Factors in Immigrants and US-Born Adults. Journal of Immigrant and Minority Health, 2020, 22, 1200-1207.	0.8	2
388	Domain-Specific Antibodies Reveal Differences in the Membrane Topologies of Apolipoprotein L1 in Serum and Podocytes. Journal of the American Society of Nephrology: JASN, 2020, 31, 2065-2082.	3.0	15
389	At the Research-Clinical Interface. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1181-1189.	2.2	9
390	Podocytopathies. Nature Reviews Disease Primers, 2020, 6, 68.	18.1	237
391	Chronic Hemodialysis Patients Hospitalized with COVID-19: Short-term Outcomes in the Bronx, New York. Kidney360, 2020, 1, 755-762.	0.9	51
392	Focal Segmental Glomerulosclerosis: State-of-the-Art and Clinical Perspective. Nephron, 2020, 144, 413-427.	0.9	56
393	Contribution of Predictive and Prognostic Biomarkers to Clinical Research on Chronic Kidney Disease. International Journal of Molecular Sciences, 2020, 21, 5846.	1.8	29
394	Association of APOL1 Genotypes With Measures of Microvascular and Endothelial Function, and Blood Pressure in MESA. Journal of the American Heart Association, 2020, 9, e017039.	1.6	7

#	Article	IF	Citations
395	APOL1 renal risk variants exacerbate podocyte injury by increasing inflammatory stress. BMC Nephrology, 2020, 21, 371.	0.8	21
396	The Contribution of Kidney Disease to Cognitive Impairment in Patients with Type 2 Diabetes. Current Diabetes Reports, 2020, 20, 49.	1.7	6
397	Trends in Living Donation by Race and Ethnicity Among Children With End-stage Renal Disease in the United States, 1995â€“2015. Transplantation Direct, 2020, 6, e570.	0.8	12
398	Profiling APOL1 Nephropathy Risk Variants in Genome-Edited Kidney Organoids with Single-Cell Transcriptomics. Kidney360, 2020, 1, 203-215.	0.9	18
399	Neighborhood context and kidney disease in Philadelphia. SSM - Population Health, 2020, 12, 100646.	1.3	6
400	Apolipoprotein L1: role in the evaluation of kidney transplant donors. Current Opinion in Nephrology and Hypertension, 2020, 29, 645-655.	1.0	18
401	Increased Incidence of Chronic Kidney Injury in African Americans Following Cardiac Transplantation. Journal of Racial and Ethnic Health Disparities, 2021, 8, 1435-1446.	1.8	2
402	Gene of the month: APOL1. Journal of Clinical Pathology, 2020, 73, 441-443.	1.0	4
403	Association of APOL1 Risk Genotype and Air Pollution for Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 401-403.	2.2	14
404	Incident Chronic Kidney Disease Risk among Hispanics/Latinos in the United States: The Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Journal of the American Society of Nephrology: JASN, 2020, 31, 1315-1324.	3.0	7
405	Genetic Testing for APOL1 Genetic Variants in Clinical Practice. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 126-128.	2.2	17
406	A bidirectional Mendelian randomization study supports causal effects of kidney function onÂbloodÂpressure. Kidney International, 2020, 98, 708-716.	2.6	70
407	Apolipoprotein L1 (APOL1) Coding Variants Are Associated With Creatinine Rise After Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 3314-3320.	0.6	4
408	APOL1 Genetic Variants Are Associated with Serum-Oxidized Low-Density Lipoprotein Levels and Subclinical Atherosclerosis in South African CKD Patients. Nephron, 2020, 144, 331-340.	0.9	2
409	Importance of Genetic Studies of Cardiometabolic Disease in Diverse Populations. Circulation Research, 2020, 126, 1816-1840.	2.0	19
410	Progression in the severity of aortic stenosis according to race among those with advanced chronic kidney disease. Cardiovascular Diagnosis and Therapy, 2020, 10, 24-30.	0.7	0
411	A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank. Journal of Hepatology, 2020, 72, 1070-1081.	1.8	35
412	Ethnic minority disparities in progression and mortality of pre-dialysis chronic kidney disease: a systematic scoping review. BMC Nephrology, 2020, 21, 217.	0.8	48

#	Article	IF	Citations
413	Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis. Kidney International Reports, 2020, 5, 1228-1239.	0.4	5
414	Effect of a Single Apolipoprotein L1 Gene Nephropathy Variant on the Risk of Advanced Lupus Nephritis in Brazilians. Journal of Rheumatology, 2020, 47, 1209-1217.	1.0	17
415	Genomeâ€wide association study for time to failure of kidney transplants from African American deceased donors. Clinical Transplantation, 2020, 34, e13827.	0.8	13
416	Phenome-wide association analysis suggests the APOL1 linked disease spectrum primarily drives kidney-specific pathways. Kidney International, 2020, 97, 1032-1041.	2.6	20
417	Nephrotoxicity in a Patient With Inadequate Pain Control: Potential Role of Pharmacogenetic Testing for Cytochrome P450 2D6 and Apolipoprotein L1. Frontiers in Pharmacology, 2019, 10, 1511.	1.6	6
418	Postâ€"Acute Kidney Injury Proteinuria and Subsequent Kidney Disease Progression. JAMA Internal Medicine, 2020, 180, 402.	2.6	98
419	Implementation of a Renal Precision Medicine Program: Clinician Attitudes and Acceptance. Life, 2020, 10, 32.	1.1	11
420	Editorial: Genetics of Kidney Diseases. Frontiers in Genetics, 2020, 11, 305.	1.1	1
421	Association Between APOL1 Genotype and Need for Kidney Replacement Therapy in Patients Without Diabetes: Does Age Matter?. American Journal of Kidney Diseases, 2020, 75, 294-296.	2.1	1
422	APOL1 Nephropathy: From Genetics to Clinical Applications. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 294-303.	2.2	119
423	Racial disparities in preemptive waitlisting and deceased donor kidney transplantation: Ethics and solutions. American Journal of Transplantation, 2021, 21, 958-967.	2.6	38
424	Association of gender, age, and race on renal outcomes and mortality in patients with severe sepsis and septic shock. Journal of Critical Care, 2021, 61, 52-56.	1.0	15
425	Using race to estimate glomerular filtration and its impact in kidney transplantation. Clinical Transplantation, 2021, 35, e14136.	0.8	20
426	Risk Factors for CKD Progression. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 648-659.	2.2	65
427	Racialized algorithms for kidney function: Erasing social experience. Social Science and Medicine, 2021, 268, 113548.	1.8	35
428	APOL1 Risk Variants and Subclinical Cardiovascular Disease in Incident Hemodialysis Patients. Kidney International Reports, 2021, 6, 333-341.	0.4	4
429	African American polycystic kidney patients receive higher risk kidneys, but do not face increased risk for graft failure or post-transplant mortality. American Journal of Surgery, 2021, 221, 1093-1103.	0.9	1
430	Race, <scp>APOL1</scp> Risk Variants, and Clinical Outcomes among Older Adults: The <scp>ARIC</scp> Study. Journal of the American Geriatrics Society, 2021, 69, 155-163.	1.3	9

#	Article	IF	Citations
431	Identifying Clinical and Genomic Features Associated With Chronic Kidney Disease. Frontiers in Big Data, 2020, 3, 528828.	1.8	1
432	Social determinants of racial and socioeconomic disparities in CKD and ESRD. , 2021, , 49-88.		2
433	Evolutionary medicineâ€"Apolipoprotein L1 in human health and disease. , 2021, , 117-129.		0
434	Subtyping CKD Patients by Consensus Clustering: The Chronic Renal Insufficiency Cohort (CRIC) Study. Journal of the American Society of Nephrology: JASN, 2021, 32, 639-653.	3.0	41
435	APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis. Human Molecular Genetics, 2021, 30, 182-197.	1.4	27
437	Precision Medicine in Kidney Transplantation: Just Hype or a Realistic Hope?. Transplantation Direct, 2021, 7, e650.	0.8	8
438	Social Determinants of Health in People with Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 803-805.	2.2	6
439	Kidney-disease-associated variants of Apolipoprotein L1Âshow gain of function in cation channel activity. Journal of Biological Chemistry, 2021, 296, 100238.	1.6	11
440	Novel genetic testing model: A collaboration between genetic counselors and nephrology. American Journal of Medical Genetics, Part A, 2021, 185, 1142-1150.	0.7	16
441	Evaluation of Genetic Kidney Disease in Living Donor Candidates. , 2021, , 189-217.		2
442	COVID-19 and Multisystem Inflammatory Syndrome in Children. Wits Journal of Clinical Medicine, 2021, 3, 33.	0.0	1
443	Racial Disparities in Eligibility for Preemptive Waitlisting for Kidney Transplantation and Modification of eGFR Thresholds to Equalize Waitlist Time. Journal of the American Society of Nephrology: JASN, 2021, 32, 677-685.	3.0	26
445	Hospitalization Trajectories and Risks of ESKD and Death in Individuals With CKD. Kidney International Reports, 2021, 6, 1592-1602.	0.4	6
446	Kidney disease and APOL1. Human Molecular Genetics, 2021, 30, R129-R137.	1.4	27
447	Association Between Midlife Obesity and Kidney Function Trajectories: The Atherosclerosis Risk in Communities (ARIC) Study. American Journal of Kidney Diseases, 2021, 77, 376-385.	2.1	13
448	Association Between APOL1 Genotype and Kidney Diseases and Annual Kidney Function Change: A Systematic Review and Meta-Analysis of the Prospective Studies. International Journal of Nephrology and Renovascular Disease, 2021, Volume 14, 97-104.	0.8	5
449	Medical records-based chronic kidney disease phenotype for clinical care and â€œbig dataâ€•observational and genetic studies. Npj Digital Medicine, 2021, 4, 70.	5.7	39
452	Diagnosis, Education, and Care of Patients with APOL1-Associated Nephropathy: A Delphi Consensus and Systematic Review. Journal of the American Society of Nephrology: JASN, 2021, 32, 1765-1778.	3.0	13

#	Article	IF	Citations
453	Toward a fine-scale population health monitoring system. Cell, 2021, 184, 2068-2083.e11.	13.5	78
454	Social Justice as a Tool to Eliminate Inequities in Kidney Disease. Seminars in Nephrology, 2021, 41, 203-210.	0.6	4
455	A Critical Look at Raceâ€Based Practices in Rheumatology Guidelines. Arthritis Care and Research, 2022, 74, 1602-1607.	1.5	3
457	Multi-Institutional Implementation of Clinical Decision Support for APOL1, NAT2, and YEATS4 Genotyping in Antihypertensive Management. Journal of Personalized Medicine, 2021, 11, 480.	1.1	6
458	Joint Associations of Maternal-Fetal APOL1 Genotypes and Maternal Country of Origin With Preeclampsia Risk. American Journal of Kidney Diseases, 2021, 77, 879-888.e1.	2.1	20
459	Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies. Pediatric Nephrology, 2022, 37, 1215-1229.	0.9	42
460	Air, Land, and Sea: Gene-Environment Interaction in Chronic Disease. American Journal of Medicine, 2021, 134, 1476-1482.	0.6	2
461	APOL1 Genetic Variants Are Associated With Increased Risk of Coronary Atherosclerotic Plaque Rupture in the Black Population. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2201-2214.	1.1	8
462	HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role. Cells, 2021, 10, 1869.	1.8	46
463	Gender and race/ethnicity differences in living kidney donor demographics: Preference or disparity?. Transplantation Reviews, 2021, 35, 100614.	1.2	10
464	Intensive Blood Pressure Control, APOL1 Genotype, and Kidney Outcomes in Individuals With Type 2 Diabetes: A Post Hoc Analysis of the Action to Control Cardiovascular Risk in Diabetes-Blood Pressure (ACCORD-BP) Trial. Kidney Medicine, 2021, 3, 874-876.	1.0	1
465	Sex Differences in Renal Function: Participation of Gonadal Hormones and Prolactin. Endocrines, 2021, 2, 185-202.	0.4	6
466	FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement?. Lancet, The, 2021, 398, 283-284.	6.3	16
467	Biomarkers of Immune Activation and Incident Kidney Failure With Replacement Therapy: Findings From the African American Study of Kidney Disease and Hypertension. American Journal of Kidney Diseases, 2021, 78, 75-84.e1.	2.1	10
468	Genetic Susceptibility to Acute Kidney Injury. Journal of Clinical Medicine, 2021, 10, 3039.	1.0	13
469	APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study. Kidney Medicine, 2021, 3, 962-973.e1.	1.0	2
470	Effects of reninâ€angiotensin blockade and APOL1 on kidney function in sickle cell disease. EJHaem, 2021, 2, 483-484.	0.4	2
471	Association of Apparent Treatment-Resistant Hypertension With Differential Risk of End-Stage Kidney Disease Across Racial Groups in the Million Veteran Program. Hypertension, 2021, 78, 376-386.	1.3	2

#	Article	IF	Citations
472	The epidemiology of kidney disease in people of African ancestry with HIV in the UK. EClinicalMedicine, 2021, 38, 101006.	3.2	12
473	Recipient APOL1 risk alleles associate with death-censored renal allograft survival and rejection episodes. Journal of Clinical Investigation, 2021, 131, .	3.9	33
474	CKD Progression From the Time of Estimated GFR-Based Waitlist Eligibility and Racial Disparities in Transplant Access. American Journal of Kidney Diseases, 2022, 79, 841-848.e1.	2.1	6
475	Apolipoprotein L1 risk genotypes in Ghanaian patients with systemic lupus erythematosus: a prospective cohort study. Lupus Science and Medicine, 2021, 8, e000460.	1.1	18
476	Association of Sickle Cell Trait With Incidence of Coronary Heart Disease Among African American Individuals. JAMA Network Open, 2021, 4, e2030435.	2.8	5
477	Novel Risk Factors for Progression of Diabetic and Nondiabetic CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2021, 77, 56-73.e1.	2.1	45
478	HDL in Infectious Diseases and Sepsis. Handbook of Experimental Pharmacology, 2015, 224, 483-508.	0.9	145
479	Focal Segmental Glomerulosclerosis, Adult. , 2017, , 1-29.		1
480	The CKiD study: overview and summary of findings related to kidney disease progression. Pediatric Nephrology, 2021, 36, 527-538.	0.9	31
481	Racial and health insurance disparities in pediatric acute kidney injury in the USA. Pediatric Nephrology, 2020, 35, 1085-1096.	0.9	13
482	Serum levels of IL-6, IL-8 and IL-10 and risks of end-stage kidney disease and mortality. Nephrology Dialysis Transplantation, 2021, 36, 561-563.	0.4	10
483	KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation, 2017, 101, S7-S105.	0.5	308
488	Association of the MYH9 Gene Polymorphisms with Chronic Renal Disease Secondary to Hypertensive Nephrosclerosis, in a Caucasian Population. American Journal of Internal Medicine, 2014, 2, 95.	0.1	1
489	Antisense oligonucleotide treatment ameliorates IFN-Î³â€“induced proteinuria in APOL1-transgenic mice. JCI Insight, 2019, 4, .	2.3	64
490	APOL1 variants change C-terminal conformational dynamics and binding to SNARE protein VAMP8. JCI Insight, 2017, 2, .	2.3	48
491	Kidney disease: new technologies translate mechanisms to cure. Journal of Clinical Investigation, 2014, 124, 2294-2298.	3.9	14
492	The Survival of Roma Minority Patients on Chronic Hemodialysis Therapy - A Romanian Multicenter Survey. PLoS ONE, 2016, 11, e0155271.	1.1	6
493	MicroRNAs in the miR-17 and miR-15 families are downregulated in chronic kidney disease with hypertension. PLoS ONE, 2017, 12, e0176734.	1.1	38

#	Article	IF	Citations
494	Apolipoprotein L1 risk variants associate with prevalent atherosclerotic disease in African American systemic lupus erythematosus patients. PLoS ONE, 2017, 12, e0182483.	1.1	21
495	Genetic susceptibility of hypertensionâ€induced kidney disease. Physiological Reports, 2021, 9, e14688.	0.7	15
496	A Putative Role of Apolipoprotein L1 Polymorphism in Renal Parenchymal Scarring Following Febrile Urinary Tract Infection in Nigerian Under-Five Children: Proposal for a Case-Control Association Study. JMIR Research Protocols, 2018, 7, e156.	0.5	1
497	BURDEN, ACCESS, AND DISPARITIES IN KIDNEY DISEASE. Nephrology (Saint-Petersburg), 2019, 23, 9-17.	0.1	2
498	Clinical Applications of Genetic Discoveries in Kidney Transplantation: a Review. Kidney360, 2020, 1, 300-305.	0.9	5
499	Initial Validation of a Machine Learning-Derived Prognostic Test (KidneyIntelX) Integrating Biomarkers and Electronic Health Record Data To Predict Longitudinal Kidney Outcomes. Kidney360, 2020, 1, 731-739.	0.9	15
500	The Relationship between APOL1 Structure and Function: Clinical Implications. Kidney360, 2021, 2, 134-140.	0.9	3
501	Chronic kidney disease in African Americans: Puzzle pieces are falling into place. Cleveland Clinic Journal of Medicine, 2017, 84, 855-862.	0.6	8
502	African origins and chronic kidney disease susceptibility in the human immunodeficiency virus era. World Journal of Nephrology, 2015, 4, 295.	0.8	25
503	Apolipoprotein L-1 renal risk variants form active channels at the plasma membrane driving cytotoxicity. ELife, 2020, 9, .	2.8	45
504	Podocytopathy in Obesity: Challenges of Living Large. Seminars in Nephrology, 2021, 41, 307-317.	0.6	2
505	Genetic Testing for Chronic Kidney Diseases: Clinical Utility and Barriers Perceived by Nephrologists. Kidney Medicine, 2021, 3, 1050-1056.	1.0	16
506	CKD in Minorities: Non-Hispanic Blacks, Hispanics, Asians, and Indian Americans. , 2022, , 333-346.		0
507	APOL1 Renal Risk Variants and Kidney Function in HIV-1â€“Infected People From Sub-Saharan Africa. Kidney International Reports, 2022, 7, 483-493.	0.4	5
508	Impact of education on APOL1 testing attitudes among prospective living kidney donors. Clinical Transplantation, 2022, 36, e14516.	0.8	3
509	Time to end the misuse of race in medicine: cases from nephrology. BMJ, The, 2021, 375, n2435.	3.0	6
510	Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study. Nephrology Dialysis Transplantation, 2022, 37, 271-284.	0.4	48
512	Collapsing Focal Segmental Glomerulosclerosis and Tubuloreticular Inclusions in Lupus â€“ A Case Report. Open Access Library Journal (oalib), 2014, 01, 1-4.	0.1	0

#	Article	IF	Citations
513	Management of Chronic Kidney Disease in Children. , 2015, , 1-68.		0
514	Management of Chronic Kidney Disease in Children. , 2016, , 2207-2266.		2
515	Overview and Classification of Genetic Diseases of the Glomerulus. , 2016, , 348-351.		0
516	Genetic Diagnosis of Renal Diseases: Basic Concepts and Testing. , 2016, , 107-149.		0
517	Health Literacy Not Associated with Chronic Kidney Disease Awareness. Health Literacy Research and Practice, 2017, 1, e117-e127.	0.5	3
518	Pediatric Nephrologist and the Infant or Child Before Kidney Transplantation. , 2018, , 1-9.		0
519	Living Donor Evaluation and Selection. , 2018, , 1-21.		0
523	Living Donor Evaluation and Selection. , 2018, , 39-59.		0
525	Risk Factors for Chronic Kidney Disease. , 2019, , 29-38.		0
526	Alemtuzumab Induction Is Associated With an Equalization of Outcomes Between White and African American Kidney Transplant Recipients. Experimental and Clinical Transplantation, 2019, 17, 196-201.	0.2	3
527	Burden, Access, and Disparities in Kidney Disease. Experimental and Clinical Transplantation, 2019, 17, 131-137.	0.2	3
528	Burden, access, and disparities in kidney disease. Terapevticheskii Arkhiv, 2019, 91, 34-39.	0.2	2
531	Apolipoprotein L1 associated nephropathy; an overview. Journal of Renal Injury Prevention, 2019, 8, 311-315.	0.6	0
532	Important Differences in Renal Disease. , 2020, , 85-94.		0
533	The Treatment with Mycophenolate Mofetil of Corticoresistent Nephrotic Syndrome by Idiopathic Focal Segmental Glomerulosclerosis: Analysis of Twenty Cases. Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki, 2019, 40, 135-137.	0.2	0
534	Interpreting the Meaning in Our Genomes: Perspectives from Biochemistry, Genetics, Infectious Disease, and Dance. , 2020, , 213-228.		0
538	Addressing the global burden of chronic kidney disease through clinical and translational research. Transactions of the American Clinical and Climatological Association, 2014, 125, 229-43; discussion 243-6.	0.9	103
539	Development and validation of an electronic phenotyping algorithm for chronic kidney disease. AMIA ... Annual Symposium proceedings, 2014, 2014, 907-16.	0.2	31

#	Article	IF	Citations
540	Disease progression subtype discovery from longitudinal EMR data with a majority of missing values and unknown initial time points. AMIA ... Annual Symposium proceedings, 2014, 2014, 709-18.	0.2	4
541	H3Africa comes of age. Cardiovascular Journal of Africa, 2015, 26, S3-5.	0.2	7
542	KIDNEY DISEASE GENETICS AND THE IMPORTANCE OF DIVERSITY IN PRECISION MEDICINE. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2016, 21, 285-96.	0.7	3
543	Burden, Access, and Disparities in Kidney Disease. Indian Journal of Nephrology, 2019, 29, 77-83.	0.2	0
544	APOL1 genotypes: Do they contribute to ethnicity-associated biological health inequalities in pregnancy?. Obstetric Medicine, 0, , 1753495X2110437.	0.5	0
545	Practice Patterns in the Acceptance of Medically Complex Living Kidney Donors with Obesity, Hypertension, Family History of Kidney Disease, or Donor-Recipient Age Discrepancy. Avicenna Journal of Medicine, 2021, 11, 172-184.	0.3	0
546	APOL1 renal risk variants are associated with obesity and body composition in African ancestry adults. Medicine (United States), 2021, 100, e27785.	0.4	6
547	An overview of renal insufficiency, race, and glomerular filtration rate calculation for the vascular surgeon. Journal of Vascular Surgery, 2022, 75, 3-4.	0.6	2
548	Alpha Globin Gene Copy Number Is Associated with Prevalent Chronic Kidney Disease and Incident End-Stage Kidney Disease among Black Americans. Journal of the American Society of Nephrology: JASN, 2022, 33, 213-224.	3.0	8
549	APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program. JAMA Internal Medicine, 2022, 182, 386.	2.6	31
550	How Genetics Can Improve Clinical Practice in Chronic Kidney Disease: From Bench to Bedside. Journal of Personalized Medicine, 2022, 12, 193.	1.1	1
551	Antisense Oligonucleotide: A Potential Therapeutic Intervention for Chronic Kidney Disease. Kidney and Dialysis, 2022, 2, 16-37.	0.5	1
552	Genetic Variants of APOL1 Are Major Determinants of Kidney Failure in People of African Ancestry With HIV. Kidney International Reports, 2022, 7, 786-796.	0.4	10
553	<i>APOL1</i> Risk Variants Associated with Serum Albumin in a Population-Based Cohort Study. American Journal of Nephrology, 2022, 53, 182-190.	1.4	0
554	Rates of Cardiovascular Disease and CKD Progression in Young Adults with CKD across Racial and Ethnic Groups. Kidney360, 2022, 3, 834-842.	0.9	4
555	The nephropathy of sickle cell trait and sickle cell disease. Nature Reviews Nephrology, 2022, 18, 361-377.	4.1	26
556	Outcomes of kidney donors with sickle cell trait: A preliminary analysis. Clinical Transplantation, 2022, , e14626.	0.8	1
557	Evaluation of Genetic Kidney Diseases in Living Donor Kidney Transplantation: Towards Precision Genomic Medicine in Donor Risk Assessment. Current Transplantation Reports, 2022, 9, 127-142.	0.9	8

#	Article	IF	Citations
558	Effects of Testing and Disclosing Ancestry-Specific Genetic Risk for Kidney Failure on Patients and Health Care Professionals. JAMA Network Open, 2022, 5, e221048.	2.8	9
559	Longitudinal TNFR1 and TNFR2 and Kidney Outcomes: Results from AASK and VA NEPHRON-D. Journal of the American Society of Nephrology: JASN, 2022, 33, 996-1010.	3.0	16
560	Integration of artificial intelligence and multi-omics in kidney diseases. Fundamental Research, 2023, 3, 126-148.	1.6	5
561	Black and White Adults With CKD Hospitalized With Acute Kidney Injury: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2022, , .	2.1	1
562	Current and future state of clinical pharmacistâ€led precision medicine initiatives. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 754-764.	0.5	3
563	Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2022, 101, 1126-1141.	2.6	46
564	Burden, access, and disparities in kidney disease. Indian Journal of Nephrology, 2019, 29, 77.	0.2	0
566	APOL1 Kidney Risk Variants and Proteomics. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 684-692.	2.2	4
567	Defining diagnostic trajectories in patients with podocytopathies. CKJ: Clinical Kidney Journal, 2022, 15, 2006-2019.	1.4	2
568	Apolipoprotein L1 High-Risk Genotypes and Albuminuria in Sub-Saharan African Populations. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 798-808.	2.2	8
569	â€œCan i donate a kidney?â€•Common questions and simplified answers to the prospective kidney donor. Journal of the National Medical Association, 2022, , .	0.6	0
570	The removal of race from kidney function estimation: Key points for primary providers. Journal of the National Medical Association, 2022, 114, S25-S33.	0.6	2
571	Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension. Contemporary Clinical Trials, 2022, 119, 106813.	0.8	2
572	Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies. Kidney International, 2022, 102, 624-639.	2.6	18
573	Determinants of severity in sickle cell disease. Blood Reviews, 2022, 56, 100983.	2.8	13
575	SLC12A3 Variation and Renal Function in Chinese Patients With Hypertension. Frontiers in Medicine, 0, 9, .	1.2	2
576	Genome-wide polygenic score to predict chronic kidney disease across ancestries. Nature Medicine, 2022, 28, 1412-1420.	15.2	48
577	Treatment potential in APOL1-associated nephropathy. Current Opinion in Nephrology and Hypertension, 2022, 31, 442-448.	1.0	7

#	Article	IF	Citations
578	Impact of SARS-CoV-2 Pandemic on food Security in Patients With chronic Kidney Disease. , 2023, 33, 78-87.		4
579	CKD Progression and Economic Burden in Individuals With CKD Associated With Type 2 Diabetes. Kidney Medicine, 2022, 4, 100532.	1.0	5
580	Obesity-related glomerulopathy in the presence of APOL1 risk alleles. BMJ Case Reports, 2022, 15, e249624.	0.2	2
581	APOL1-Associated Kidney Disease. , 2023, , 125-139.		0
582	Serum Cystatin-C is linked to increased prevalence of diabetes and higher risk of mortality in diverse middle-aged and older adults. PLoS ONE, 2022, 17, e0270289.	1.1	6
583	Apolipoprotein L1 Genotypes and the Association of Urinary Potassium Excretion with CKD Progression. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 1477-1486.	2.2	2
584	SMOC2 gene interacts with APOL1 in the development of end-stage kidney disease: A genome-wide association study. Frontiers in Medicine, 0, 9, .	1.2	0
585	APOL1 variant-expressing endothelial cells exhibit autophagic dysfunction and mitochondrial stress. Frontiers in Genetics, 0, 13, .	1.1	7
586	APOL1 Genotype, Proteinuria, and the Risk of Kidney Failure: A Secondary Analysis of the AASK (African) Tj ETQq0 0 0 rgBT /Overlock 10 Studies. Kidney Medicine, 2022, 4, 100563.	1.0	2
589	Identification of Novel Phenotypes Correlated with CKD: A Phenotype-Wide Association Study. International Journal of Medical Sciences, 2022, 19, 1920-1928.	1.1	1
591	Seeking justice, equity, diversity and inclusion in pediatric nephrology. Frontiers in Pediatrics, 0, 10, .	0.9	2
592	Apolipoprotein L1 gene variants and kidney disease in patients with HIV: a systematic review and meta-analysis. Journal of Nephrology, 2023, 36, 1119-1134.	0.9	3
593	Ethnic disparities in pregnancy-related acute kidney injury in a United Kingdom population. Journal of Nephrology, 0, , .	0.9	0
594	Biochemical and molecular genetic markers of kidney damage in hypertension. Arterial Hypertension (Russian Federation), 2023, 28, 614-626.	0.1	2
595	Short-term air pollution exposure associated with death from kidney diseases: a nationwide time-stratified case-crossover study in China from 2015 to 2019. BMC Medicine, 2023, 21, .	2.3	10
596	APOL1 and APOL1-Associated Kidney Disease: A Common Disease, an Unusual Disease Gene â€“ Proceedings of the Henry Shavelle Professorship. Glomerular Diseases, 0, , 75-87.	0.2	5
597	Rationale and Design of the Diet, CKD, and Apolipoprotein L1 Study in Low-Income and Middle-Income Countries. Kidney International Reports, 2023, , .	0.4	0
598	Rapid Progression of Focal Segmental Glomerulosclerosis in Patients with High-Risk APOL1 Genotypes. Clinical Journal of the American Society of Nephrology: CJASN, 2023, 18, 344-355.	2.2	3

#	Article	IF	Citations
599	Screening for Kidney Disease in Low- and Middle-Income Countries. Seminars in Nephrology, 2022, 42, 151315.	0.6	5
600	The Impact of Low Socioeconomic Status on Progression of Chronic Kidney Disease in Low- and Lower Middle-Income Countries. Seminars in Nephrology, 2022, 42, 151338.	0.6	2
601	Clinical and Genetic Characteristics of CKD Patients with High-Risk APOL1 Genotypes. Journal of the American Society of Nephrology: JASN, 2023, 34, 909-919.	3.0	4
602	Genetic evaluation of living kidney donor candidates: A review and recommendations for best practices. American Journal of Transplantation, 2023, 23, 597-607.	2.6	3
603	Dietary Patterns, Apolipoprotein L1 Risk Genotypes, and CKD Outcomes Among Black Adults in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study. Kidney Medicine, 2023, 5, 100621.	1.0	0
604	Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. New England Journal of Medicine, 2023, 388, 969-979.	13.9	42
605	Develop and Validate a Risk Score in Predicting Renal Failure in Focal Segmental Glomerulosclerosis. Kidney Diseases (Basel, Switzerland), 2023, 9, 285-297.	1.2	0
606	Molecular Diagnosis of Genetic Diseases of the Kidney: Primer for Pediatric Nephrologists. , 2023, , 119-169.		0
607	Steroid Resistant Nephrotic Syndrome. , 2023, , 443-469.		0
608	Chronic Kidney Disease Management in Developing Countries. , 2023, , 1-146.		0
609	Racial Disparities Among Lung Transplant Survivorsâ€"Shadows and Substance. JAMA Network Open, 2023, 6, e238285.	2.8	1
610	HDL and chronic kidney disease. Atherosclerosis Plus, 2023, 52, 9-17.	0.3	2
611	Angelica decursiva exerts antihypertensive activity by inhibiting L-type calcium channel. Journal of Ethnopharmacology, 2023, 313, 116527.	2.0	2
621	Inaxaplin for the treatment of APOL1-associated kidney disease. Nature Reviews Nephrology, 2023, 19, 479-480.	4.1	1
623	The metabolic effects of APOL1 in humans. Pflugers Archiv European Journal of Physiology, 2023, 475, 911-932.	1.3	0
644	The Inclusion of Racial and Ethnic Minority Groups in Clinical Trials. The International Library of Bioethics, 2023, , 37-56.	0.1	0
645	Kidney transplantation: the recipient. , 2024, , 411-691.		0
648	Cultural differences in living organ donation. , 2024, , 9-44.		0

#	Article	IF	Citations
650	Update in Pediatric Nephrology. , 2023, , 523-550.		0